Table 1 Demographics and comorbidities of patients with COVID-19
From: Associated risk factors with disease severity and antiviral drug therapy in patients with COVID-19
Variables | All Patients (n = 550) | Severe (n = 178) | Non-severe (n = 372) | p value |
|---|---|---|---|---|
Age, years, n (%) | ||||
  < 44 | 103 (18.7%) | 13 (7.3%) | 90 (24.2%) | < 0.001 |
 45–59 | 170 (30.9%) | 36 (20.2%) | 134 (36.0%) | < 0.001 |
  ≥ 60 | 277 (50.4%) | 129 (72.5%) | 148 (39.8%) | < 0.001 |
Sex, n (%) | ||||
 Female | 292 (53.1%) | 74 (41.6%) | 218 (58.6%) | < 0.001 |
 Male | 258 (46.9%) | 104 (58.4%) | 154 (41.4%) | < 0.001 |
Source of transmission, n (%) | ||||
 None | 342 (62.2%) | 144 (80.9%) | 198 (53.2%) | < 0.001 |
 Contact history with diagnosed patients | 170 (30.9%) | 22 (12.4%) | 148 (39.8%) | < 0.001 |
 Recent visit of COVID-19 designated hospitals | 38 (6.9%) | 12 (6.7%) | 26 (7.0%) | < 0.001 |
Comorbidity, n (%) | ||||
 Hypertension | 184 (33.5%) | 81 (45.5%) | 103 (27.7%) | < 0.001 |
 Diabetes | 77 (14.0%) | 37 (20.8%) | 40 (10.8%) | 0.002 |
 Cardiovascular disease | 56 (10.2%) | 26 (14.6%) | 30 (8.1%) | 0.018 |
 Malignancy | 23 (4.2%) | 13 (7.3%) | 10 (2.7%) | 0.011 |
 Cerebrovascular disease | 20 (3.6%) | 10 (5.6%) | 10 (2.7%) | 0.086 |
 Chronic pulmonary disease | 18 (3.3%) | 7 (3.9%) | 11 (3.0%) | 0.547 |
 Chronic liver disease | 15 (2.7%) | 4 (2.2%) | 11 (3.0%) | 0.843 |
 Hyperlipidemia | 10 (1.8%) | 5 (2.8%) | 5 (1.3%) | 0.229 |